# Subcutaneous Piperacillin/Tazobactam Compared With Intravenous Treatment

> **NCT07481539** · PHASE2 · RECRUITING · sponsor: **Azienda Sanitaria Universitaria Friuli Centrale** · enrollment: 240 (estimated)

## Conditions studied

- Bacteria Infection
- Piperacillin, Tazobactam Drug Combination

## Interventions

- **DEVICE:** Piperacillin, Tazobactam Drug Combination
- **DRUG:** Piperacillin, Tazobactam Drug Combination

## Key facts

- **NCT ID:** NCT07481539
- **Lead sponsor:** Azienda Sanitaria Universitaria Friuli Centrale
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-24
- **Primary completion:** 2027-04-30
- **Final completion:** 2027-04-30
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07481539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07481539, "Subcutaneous Piperacillin/Tazobactam Compared With Intravenous Treatment". Retrieved via AI Analytics 2026-09-25 from https://api.ai-analytics.org/clinical/NCT07481539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*